当前位置: 首页 >> 检索结果
4417. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
作者: Tze-Fan Chao.;Chern-En Chiang.;Jo-Nan Liao.;Tzeng-Ji Chen.;Gregory Y H Lip.;Shih-Ann Chen.
来源: Chest. 2020年157卷5期1266-1277页
Stroke prevention in elderly patients with atrial fibrillation (AF) can be challenging, requiring a balance between thromboembolism prevention and serious bleeding. Comparisons of nonvitamin K antagonist oral anticoagulants (NOACs) and warfarin in older adults at different age strata (65-74, 75-89, and ≥ 90 years of age) in the daily practice have not been well described, particularly in Asians. We aimed to assess the clinical outcomes of NOACs compared with warfarin for stroke prevention in elderly patients with AF.
4418. Reference Standards for Ventilatory Threshold Measured With Cardiopulmonary Exercise Testing: The Fitness Registry and the Importance of Exercise: A National Database.
作者: Baruch Vainshelboim.;Ross Arena.;Leonard A Kaminsky.;Jonathan Myers.
来源: Chest. 2020年157卷6期1531-1537页
Established reference standards for the ventilatory threshold (Vt) are lacking. The aim of this study was to develop reference standards for the Vt derived from cardiopulmonary exercise testing (CPX) using treadmill and cycle ergometry.
4419. Postembolotherapy Pulmonary Arteriovenous Malformation Follow-Up: A Role for Graded Transthoracic Contrast Echocardiography Prior to High-Resolution Chest CT Scan.
作者: Daniel M DePietro.;Nicole R Curnes.;Jesse Chittams.;Victor A Ferrari.;Reed E Pyeritz.;Scott O Trerotola.
来源: Chest. 2020年157卷5期1278-1286页
High-resolution chest CT (HRCT) scan is recommended after pulmonary arteriovenous malformation (PAVM) embolotherapy to assess for PAVM persistence and untreated PAVM growth. Graded transthoracic contrast echocardiography (TTCE) predicts the need for embolotherapy in PAVM screening. This study sought to determine whether postembolotherapy graded TTCE can similarly predict the need for repeat embolotherapy.
4420. Is Mortality a Useful Primary End Point for Critical Care Trials?
Mortality has long been used as a primary end point for randomized controlled trials in critical care. Recently, a plurality of trials targeting mortality end points as their primary outcome has failed to detect a difference between study arms. While there are a number of reasons for the preponderance of such neutral trials, the use of mortality as an outcome is one important consideration. We explore some of the reasons why such trials may be biased toward a neutral result, as well as reasons to consider alternative end points that are better coupled to the expected therapeutic effect. We also discuss to what extent mortality as a binary outcome is patient-important in the ICU.
|